4:07 PM ET
10-Q
Financial Results
Skye Bioscience Q3 2026 Results: Turns Profitable, Net Income $69.1K
Skye Bioscience reported a significant decrease in cash and short-term investments from $25.7 million at year-end 2025 to $4.8 million as of September 30, 2026. The company experienced a net loss of $23.2 million for the first nine months of 2026, driven primarily by $13.2 million in research and development expenses. A 1-for-8 reverse stock split was effected on August 24, 2026.
- Key figure
- Net income $69.1K